Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veru Inc (VERU)
:VERU
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 7.27%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials with enobosarm, showcasing positive results in muscle preservation and fat loss. The strategic sale of the FC2 business and financial gains from debt extinguishment were also notable. However, financial challenges such as the loss on sale of the FC2 business, increased R&D costs, negative cash flow, and limited cash runway were concerning.Company Guidance
During the recent investor conference call, Veru Inc. provided comprehensive guidance on its clinical progress and financial status. The company reported positive top-line results from the Phase 2b QUALITY study, demonstrating enobosarm's efficacy in preserving lean mass and augmenting fat loss in older obese patients, with a 71% relative reduction in lean mass loss and a p-value of 0.002. The 3 mg dose of enobosarm plus semaglutide showed a 99% mean relative reduction in lean mass loss (p-value <0.001) and a 46% greater relative loss of fat mass with the 6 mg dose compared to placebo plus semaglutide (p-value = 0.014). Veru also highlighted its strategic shift towards biopharmaceuticals following the sale of its FC2 female condom business, which generated net proceeds of $16.4 million. Financially, Veru reported a net loss of $1.8 million from continuing operations, with a total cash balance of $26.6 million as of December 31, 2024. The company plans to pursue a Phase III study for enobosarm, leveraging its promising Phase 2b results, and is exploring the development of sabizabulin for treating inflammation in atherosclerotic cardiovascular disease.Successful Phase 2b QUALITY Clinical Study
The Phase 2b QUALITY clinical study showed positive top line results for enobosarm, meeting its primary endpoint with a 71% relative reduction in lean mass loss (p-value of 0.002). The enobosarm 3-milligram dose achieved a greater than 99% mean relative reduction in lean mass loss (p-value < 0.001).
Enobosarm's Impact on Fat Loss
Enobosarm treatment resulted in a 46% greater relative loss of fat mass compared to placebo plus semaglutide group at 16 weeks (p-value of 0.014). The enobosarm 3-milligram dose led to a 99.1% fat loss.
Improvement in Physical Function
The enobosarm plus semaglutide group showed a 54.4% mean relative reduction in the proportion of subjects losing at least 10% stair climb power compared to the placebo group (p-value of 0.0049).
Strategic Focus on Biopharmaceutical Development
Veru sold its FC2 female condom business for $18 million, allowing the company to focus on drug development.
Financial Gains from Debt Extinguishment
Veru recorded a gain on extinguishment of debt of $8.6 million related to the termination of the residual royalty agreement.
---
VERU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VERU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $0.55 | $0.52 | -5.45% |
| Aug 08, 2024 | $0.77 | $0.81 | +5.19% |
| May 08, 2024 | $1.63 | $1.43 | -12.27% |
| Feb 08, 2024 | $0.44 | $0.41 | -6.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Veru Inc (VERU) report earnings?
Veru Inc (VERU) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Veru Inc (VERU) earnings time?
Veru Inc (VERU) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VERU EPS forecast?
VERU EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.
---